At Santa Ana Bio we are developing novel therapeutics including monoclonals, bi-specifics and antibody drug conjugates to treat patients with serious immune mediated diseases.

SAB01 inhibits c-Kit, a validated target on the mast cells that drive a variety of allergic diseases. Historically this target has had toxicity limitations including infections, neutropenia and low sperm counts due to its expression on a variety of other cell types. To overcome this, Santa Ana designed a bi-specific that conditionally blocks c-Kit only in the presence of an undisclosed anchor target shown to be restricted to mast cells. In vitro and in vivo, SAB01 showed conditional activity against mast cells. SAB01 has been named as a development candidate, with Phase I testing expected to start next year in chronic inducible urticaria.

SAB03 agonizes PD-1, a clinically validated target in rheumatoid arthritis. Current approaches of modulating the target do not address all antigen-reactive T cells. In contrast, Santa Ana’s molecule eliminates and suppresses high-, medium- and low-expressing PD-1 pathogenic T cells. SAB03 has been named as a development candidate, with Phase I testing expected to start next year for a variety of severe inflammatory conditions.

Santa Ana’s SAB05 ADC program employs a novel technology for antibody-glucocorticoid conjugates. This approach allows the company to safely harness the long-established therapeutic efficacy of glucocorticoids while bypassing the collateral damage associated with the use of such drugs.